Inflammation Related to Muted Pleasure Feelings in Depression
the Psychiatry Advisor take:
People that have high levels of inflammation in their brain may also have more stubborn symptoms of depression.
Jennifer Felger, PhD, of Emory University School of Medicine, Atlanta, and colleagues examined 48 patients with depression. Those with high levels of high levels of the inflammatory marker CRP (C-reactive protein) were linked with a “communication failure,” as seen through brain scans, between regions of the brain important for motivation and reward.
The findings, according to Felger, reinforce the idea that high-inflammation depression is a distinct form of the mood disorder, and should have treatments developed specifically for it, she wrote in the journal Molecular Psychiatry.
In particular, many people with depression, despite taking antidepressants, still suffer from anhedonia, or the inability to feel pleasure. And in particular, those with high CRPs levels were particular susceptible to it.
“Our data suggest that by blocking inflammation or its effects on the brain, we may be able to reverse anhedonia and help depressed individuals who fail to respond to antidepressants,” Felger said in a statement.
The researchers are next planning to test whether L-DOPA, a drug that targets the brain chemical dopamine, can increase connectivity in reward-related brain regions in patients with high-inflammation depression.
Depressed patients with high levels of an inflammatory marker in their blood were particularly susceptible to anhedonia.
About one third of people with depression have high levels of inflammation markers in their blood. New research indicates that persistent inflammation affects the brain in ways that are connected with stubborn symptoms of depression, such as anhedonia, the inability to experience pleasure.
The results were published online in Molecular Psychiatry.
The findings bolster the case that the high-inflammation form of depression is distinct, and are guiding researchers' plans to test treatments tailored for it.
Anhedonia is a core symptom of depression that is particularly difficult to treat, says lead author Jennifer Felger, PhD, assistant professor of psychiatry and behavioral sciences at Emory University School of Medicine and Winship Cancer Institute.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Should Physicians Treat Family and Friends? Three Experts Weigh In
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Influence of Psychostimulants on BMI and Height in Youth With ADHD
- Dialectical Behavior Therapy Effective in Reducing Suicide Attempts, Self-Harm in Adolescents
- Medication Adherence Predictors in Patients With Severe Psychiatric Disorders
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Substance Abuse and Primary Psychosis: A Closer Look
- Functional Restoration for Chronic Pain and Depression in the Elderly: Pharmacotherapy and Beyond
- Efficacy of Long-Acting Injectable Antipsychotics vs Oral Antipsychotics
- Older Age Associated With Worse Major Depressive Disorder Outcomes
- Preoperative Psychiatric Diagnoses Not Associated With Bariatric Surgery Outcomes
- Medical Clearance of Psych Patients in the ED: Consensus Recommendations